- Price
- $203.01
- Day
- +2.45%
- Mkt Cap
- $30.72B
- 52W Range
- $88.00 – $205.93
- Volume
- 2.95M
- Beta
- 1.47
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Illumina (ILMN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Read full article
Illumina, Inc. (ILMN) Q2 2026 Earnings Call Transcript
Read full article
SAN DIEGO, July 30, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the second quarter of fiscal year 2026. Second quarter 2026 results Revenue of $1.16 billion for Q2 2026, up 9.5% from Q2 2025 and up 8.1% excluding the impacts of currency, acquisitions, and China ("ROW1 organic revenue growth") GAAP operating margin of 21.1% and non-GAAP operating margin of 22.5% GAAP diluted EPS of $1.35 and non-GAAP diluted EPS of $1.31 "Illumina delivered strong results during the second quarter.
Read full article
Illumina (ILMN) came out with quarterly earnings of $1.31 per share, beating the Zacks Consensus Estimate of $1.23 per share. This compares to earnings of $1.19 per share a year ago.
Read full article
The headline numbers for Illumina (ILMN) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read full article
Get a deeper insight into the potential performance of Illumina (ILMN) for the quarter ended June 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Read full article
Sale of Mass Cytometry Business to Multiplex Bio Ensures Full Continuity of CyTOF and Hyperion Product Lines, Customer Relationships, Dedicated Team and Continued Investment in Next Generation Multiplex Platforms
Read full article
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and Illumina (ILMN). But which of these two stocks is more attractive to value investors?
Read full article
CHICAGO--(BUSINESS WIRE)---- $ILMN #AI--Fishbone Advisors, a capital markets intelligence firm, today released a new report showing that healthcare's AI narrative has a credibility problem with institutional investors. In every healthcare subsector, roughly half to two-thirds of investors (48% to 67%) agree that management overemphasizes AI relative to its actual financial contribution, the most consistent finding in “Hallucinating Value: Healthcare's AI Narrative.” The findings come from the Fishbone Health.
Read full article
Amova Asset Management Americas Inc. trimmed its position in Illumina, Inc. (NASDAQ: ILMN) by 18.6% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The fund owned 721,532 shares of the life sciences company's stock after selling 165,333 shares during the period. Illumina comprises 1.3% of Amova
Read full article
Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid advances in personalized medicine and synthetic biology continue to transform the industry.
Read full article
Partners will use unprecedented data scale to advance more precise medicines to approval SAN DIEGO, July 16, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that the Billion Cell Atlas alliance has added three new member companies, including AI-native drug developer Formation Bio. As leaders in AI-driven drug discovery, design, and development, alliance members will use the unprecedented scale of Illumina's genome-wide perturbation data as infrastructure for the next generation of therapeutics.
Read full article